ϟ
DOI: 10.1182/blood-2013-03-488676
¤ OpenAccess: Bronze
This work has “Bronze” OA status. This means it is free to read on the publisher landing page, but without any identifiable license.
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study
Alessandra Larocca,Vittorio Montefusco,Sara Bringhen,Davide Rossi,Claudia Crippa,Roberto Mina,Mónica Galli,Magda Marcatti,Giacinto La Verde,Nicola Giuliani,Valeria Magarotto,Tommasina Guglielmelli,Delia Rota–Scalabrini,Paola Omedè,Alberto Santagostino,Ileana Baldi,Angelo Michele Carella,Mario Boccadoro,Paolo Corradini,Antônio Palumbo
Pomalidomide
Lenalidomide
Prednisone
2013
Loading...
- MLA
- APA
- Chicago
- IEEE
- Harvard
- BibTeX
Cite this:
Generate Citation
“Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study” is a paper by Alessandra Larocca Vittorio Montefusco Sara Bringhen Davide Rossi Claudia Crippa Roberto Mina Mónica Galli Magda Marcatti Giacinto La Verde Nicola Giuliani Valeria Magarotto Tommasina Guglielmelli Delia Rota–Scalabrini Paola Omedè Alberto Santagostino Ileana Baldi Angelo Michele Carella Mario Boccadoro Paolo Corradini Antônio Palumbo published in 2013. It has an Open Access status of “bronze”. You can read and download a PDF Full Text of this paper here.